000			02086cam a2200169 4500500
005			20251012013221.0
041			_afre
042			_adc
100	1	0	_aMorand, Aurélie _eauthor
700	1	0	_a Lesage, Lucile _eauthor
245	0	0	_aThe consequences of antibiotic therapy on the intestinal flora of newborns
260			_c2025.
500			_a48
520			_aThe human intestinal flora develops during the first three years of life. Its development is influenced by the maternal diet, the mother’s exposure to antibiotics during pregnancy and breastfeeding, the mode of delivery (vaginal birth or cesarean), the method of feeding (breast milk or infant formula), dietary diversification, exposure to infections, particularly gastrointestinal infections, and the use of proton pump inhibitors and antibiotics. This period is both a window of opportunity and a time of vulnerability, as the intestinal microbiota has limited resilience before the age of three. In cases of dysbiosis, the short-term risk is an overgrowth of pathogenic bacteria, which can lead to gut translocation and sepsis. In the longer term, dysbiosis—together with genetic factors, host immunity, and other exogenous factors—may contribute to the emergence of allergic, inflammatory, and autoimmune diseases. It is therefore important to preserve the intestinal flora by limiting antibiotic use to well-defined indications and, whenever possible, to use narrow-spectrum antibiotics with low gastrointestinal excretion. The development of microbiota-based therapies could play an important role in the future. It remains necessary to continue developing reliable investigative strategies and standardized benchmarks, supported by large cohort studies of newborns and infants, to further our understanding of the mechanisms underlying host–microorganism–environment interactions.
786	0		_nMédecine thérapeutique / Pédiatrie | 26 | 2 | 2025-04-15 | p. 85-89 | 1286-5494
856	4	1	_uhttps://shs.cairn.info/journal-medecine-therapeutique-pediatrie-2024-2-page-85?lang=en&redirect-ssocas=7080
999			_c1528780 _d1528780